ASAlvaro Roldán Sevilla

Alvaro Roldán Sevilla

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alvaro Roldán Sevilla has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • María José Ruiz-Olgado

    Department of Cardiology, Hospital Virgen de la Concha, Gerencia Regional de Salud de Castilla y León, Zamora, Spain (M.J.R.O., L.R.E.).

    2 shared publications
  • A. M. Merino-Merino

    Inherited Cardiovascular Disease Unit, Cardiology Department, Burgos University Hospital, Spain

    1 shared publication
  • Adolfo Fontenla

    Cardiology Department, Hospital Universitario Quironsalud Madrid, Madrid, Spain; Department of Medicine, Faculty of Medicine, Health and Sports, Universidad Europea de Madrid, Madrid, Spain

    1 shared publication
  • Adrián Lozano Ibáñez

    Servicio de Cardiología, Instituto de Ciencias del Corazón (ICICOR), Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain

    1 shared publication
  • Alfonso Mayorga

    Department of Cardiology, Hospital de El Bierzo (A.M., E.M.), Gerencia Regional de Salud de Castilla y León, Spain

    1 shared publication
  • Ana María Merino

    University Hospital of Salamanca, Department of Cardiology, University Hospital of Burgos (A.M.M., A.R.), Gerencia Regional de Salud de Castilla y León, Spain

    1 shared publication

Latest Publications

  • Open Access

    Natural Missplicing Events Amplified by an Elusive Deep-Intronic MYBPC3 Variant Cause Hypertrophic Cardiomyopathy

    by María Gallego-Delgado, Sandra Milagros Lorenzo Hernández, Soledad García Hernández, Sara Rodríguez-Diego, David Hansoe Heredero-Jung, Emilia Maneiro Pampín, Marlene Pérez-Barbeito, Mónica García Monsalvo, Belén García-Berrocal, Luis M. Rincón, et al.

    BACKGROUND: Disruption of MYBPC3 precursor mRNA splicing is a frequent genetic cause of hypertrophic cardiomyopathy (HCM). Most often, it reflects changes at canonical sites or the creation of novel splice sites. Prediction tools usually prioritize splice variants with lower efficiency when they are distant from canonical sites. These elusive variants may explain HCM in patients considered genotype-negative after DNA testing. METHODS: Massively parallel sequencing identified the previously unreported deep-intronic variant MYBPC3 c.2308+227G>A in a cohort of genotype-negative patients with HCM from Salamanca, Spain. SpliceAI predicted a benign effect (Δ score, 0.03). However, its recurrent detection prompted us to conduct extensive analyses to investigate its pathogenicity, including genetic testing, clinical assessment, family studies, splicing assays, and haplotype reconstruction. RESULTS: We identified 35 unrelated HCM probands carrying c.2308+227G>A, plus 46 relatives from 27 families, yielding 81 confirmed carriers. Of these, 56 (69%) met diagnostic criteria for HCM (66% male; mean age, 53±15 years). By age 60 years, cumulative penetrance was estimated to be 81% in women and 96% in men. The combined logarithm of the odds score of 5.51 across 20 informative families provided strong evidence of cosegregation. During follow-up of probands, no significant differences were observed in heart failure, arrhythmic events, atrial fibrillation, or mortality when compared with cohorts carrying other pathogenic MYBPC3 variants. Blood splicing assays, confirmed in cardiac tissue, showed that c.2308+227G>A disrupts splicing by the use of pre-existing cryptic donor (c.2308+299) and acceptor (c.2309−580) splice sites, generating 2 misspliced mRNAs with partial intron retention or cryptic exon inclusion, which encode truncated proteins. These cryptic sites are the leading natural, unannotated missplicing events in intron 23, and some of the most frequent across the whole MYBPC3 precursor mRNA, as revealed by SpliceVault analysis of RNA sequencing databases. This deep-intronic variant does not alter essential splice motifs but promotes the use of pre-existing cryptic sites, likely through gain of splicing regulatory enhancer elements. The identification of a shared haplotype among HCM probands carrying this variant explains its recurrent detection, consistent with an ancient founder effect. CONCLUSIONS: MYBPC3 c.2308+227G>A is a pathogenic splice-altering variant that causes HCM by amplifying natural missplicing events. These background splicing errors help explain how this elusive variant disrupts splicing without creating novel essential splice sites, thereby expanding the known mechanisms by which deep-intronic variants alter MYBPC3 splicing and ultimately contribute to HCM pathogenesis. Elusive MYBPC3 splice-altering variants should be considered in HCM patients with an unresolved genetic origin of disease.

  • Open Access

    Prognostic Factors of Acute Heart Failure: A Regional Population Registry

    by Juan Asensio-Nogueira, Miguel Rodriguez-Santamarta, Javier Tobar-Ruíz, Pedro Daniel Perdiguero-Martín, Inés Toranzo-Nieto, Clea González-Maniega, Adrián Lozano-Ibáñez, Lucía Moreno-De-Redrojo Cortes, Manuel Carrasco-Moraleja, Álvaro Margalejo-Franco, et al.

    Introduction and objectives: Acute heart failure (AHF) is the leading cardiovascular cause of hospitalization and remains associated with high mortality and rehospitalization rates. Contemporary real-world data from cardiology departments are scarce. We aimed to identify admission characteristics associated with one-year outcomes in patients hospitalized with AHF. Methods: RECYLICA is a prospective, multicentre, regional registry including consecutive patients admitted with AHF to cardiology departments across 10 hospitals over a one-year period. Patients were followed for 12 months. The primary endpoint was the composite of all-cause mortality or heart failure (HF) rehospitalization. Results: A total of 602 patients were included (37.0% women; mean age 72.6 ± 12.0 years), of whom 47.4% had heart failure with reduced left ventricular ejection fraction (HFrEF). During follow-up, 83 patients (13.8%) died and 105 (17.4%) were rehospitalized because of HF. Independent predictors of the primary endpoint were elevated admission N-terminal pro-B-type natriuretic peptide (NT-proBNP), atrial fibrillation (AF), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), previous HF, prior implantable cardioverter-defibrillator (ICD) implantation, and higher left ventricular ejection fraction (LVEF). Among patients with HFrEF, less comprehensive implementation of guideline-directed medical therapy (GDMT) at discharge was associated with significantly worse outcomes. Conclusions: In patients hospitalized with AHF, prognosis is primarily determined by comorbidity burden, admission NT-proBNP levels, previous HF, and LVEF. Among patients with HFrEF, more comprehensive implementation of GDMT at discharge was associated with improved clinical outcomes, supporting early optimization of evidence-based therapy during hospitalization.

  • Clinical and genetic features of AGel amyloidosis caused by novel gelsolin variant and its impact on cardiac function and conduction disorders

    by A. Roldán-Sevilla, M. Gallego-Delgado, M. T. Lista-Araujo, J. Torres-Pérez, A. M. Merino-Merino, C. Gil-Polo, D. Cantero-Lozano, S. M. Lorenzo-Hernandez, R. Eiros-Bachiller


  • Seasonal influence on sleep apnoea recorded daily by pacemakers

    by Alvaro Roldán Sevilla, Trinidad Díaz Cambriles, María Victoria Villena Garrido, Adolfo Fontenla, Ana Isabel Santos Sanchez, Lola Villagraz Tecedor, Juan Asensio Nogueira, Sergio Huertas Nieto, F. Javier García Fernández

    Purpose Obstructive sleep apnoea (OSA) and cardiac conduction disorders are pathologies with a rising prevalence due to increased life expectancy. Upper airway patency is affected by environmental factors that may be associated with seasonal periods. The ability to record the degree of nocturnal apnoea on a daily basis may provide a more accurate picture of seasonal variability. Methods This study used an observational, cross-sectional design recruiting consecutive patients with Sorin/Livanova/Microport® pacemakers. The study assessed the seasonal influence on the daily degree of nocturnal apnoea over a minimum period of 180 days. The respiratory events were recorded using a pacemaker-integrated detection algorithm based on transthoracic impedance variation. A generalised linear repeated measure mixed model was used to study the seasonal effect. Results A sample of 101 subjects with a mean of 227 valid nights was compiled. Summer was associated with higher RDI (respiratory disturbance index) values and winter with lower values. The mean daily RDI ratio in summer was 1.099 times higher than in winter. Conclusions Slight seasonal influences on the degree of nocturnal apnoea were detected through the daily observation of an unselected sample of pacemaker wearers. The degree of apnoea is higher in warmer months and lower in colder months.